Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Parkinson's Disease
79%
Leucine-rich Repeat Kinase 2 (LRRK2)
46%
Patients with Parkinson's Disease
34%
Huntington's Disease
32%
Parkinson Patients
21%
Single Center
20%
LRRK2 Gene
19%
Advanced Parkinson's Disease
18%
Levodopa-carbidopa Intestinal Gel
18%
Movement Disorders
17%
Idiopathic PD
15%
Dystonia
15%
GBA1
14%
Disease Duration
14%
Healthy Controls
13%
Montreal Cognitive Assessment (MoCA)
13%
Subthalamic nucleus
13%
Deep Brain Stimulation
12%
Dysphagia
12%
Israel
11%
Non-motor
11%
Speech Features
10%
Mutation Carriers
10%
Botulinum Neurotoxin (BoNT)
10%
L-DOPA
10%
Non-demented
10%
Mini-Mental State Examination
10%
Mountain Jews
9%
Ethnic Cluster
9%
Karaites
9%
Asleep Deep Brain Stimulation
9%
Unified Dyskinesia Rating Scale
9%
Life Studies
9%
Antiparkinsonian Drugs
9%
First Treatment
9%
Brain-machine Interface
9%
Treatment Patterns
9%
Heart Rate Variability
9%
Hebrew Version
9%
Spike Trains
9%
Creative Thinking
9%
Dopaminergic Therapy
9%
Medical Cannabis
9%
Family Study
9%
Botulinum Toxin Injection
9%
Human Thalamus
9%
Genetic Diagnostics
9%
Intermediate nucleus
9%
Cervical Dystonia
9%
Microelectrode Recording
9%
Neuroscience
Parkinson's Disease
100%
Leucine Rich Repeat Kinase 2
18%
Carbidopa/Levodopa
18%
Subthalamic Nucleus
14%
Deep Brain Stimulation
13%
Dystonia
12%
Cannabis
12%
Thalamus
11%
L-DOPA
11%
Montreal Cognitive Assessment
10%
Ataxia
9%
Clostridium Botulinum Type A
9%
Dopaminergic
9%
Heart Rate Variability
9%
Essential Tremor
9%
Machine Learning Algorithm
9%
Actigraphy
9%
Alzheimer's Disease
9%
Mild Cognitive Impairment
9%
Ketamine
9%
Antiphospholipid Syndrome
9%
Cannabinoid
9%
Botulinum Toxin A
9%
Gait
9%
Nucleus
9%
Dopamine Agonist
9%
Tremor
9%
Tauopathy
9%
Side Effect
8%
Stereotypic Movement Disorder
7%
Apomorphine
7%
Medicine and Dentistry
Huntington's Disease
18%
Injection
14%
Plummer-Vinson Syndrome
12%
Parkinson's Disease
12%
Stereotypic Movement Disorder
11%
Genetics
11%
Fiber Optics
9%
Ketamine
9%
Clostridium Botulinum Type A
9%
Deep Brain Stimulation
9%
Botulinum Toxin A
9%
Tau
9%
Ataxia
9%
Tauopathy
9%
Electromyography
9%
Spasmodic torticollis
9%
Anatomic Landmark
9%
Levodopa
9%
Disease Duration
9%
Cohort Analysis
9%
Next Generation Sequencing
9%
Genetic Screening
9%
Diseases
8%
Cerebellar Ataxia
7%
Antiparkinson Agent
7%
Microelectrode
6%
Dopamine Agonist
6%
DeJerine-Sottas Disease
6%